< Back to previous page
Researcher
Ignace Vergote
- Disciplines:Gynaecology and obstetrics, Nursing, Endocrinology and metabolic diseases
Affiliations
- Gynaecological Oncology (Division)
Member
From1 Jan 2012 → Today
Projects
1 - 10 of 12
- Exploring the heterogeneity of rare ovarian cancerDefining (epi)genomic transition from precursor lesion to invasive rare ovarian cancerFrom1 Apr 2020 → 1 Apr 2024Funding: Own budget, for example: patrimony, inscription fees, gifts
- Predictive genetic markers for targeted therapy in gynaecological malignancies: bridging the gap between “one-size-fits-all” and more personalised treatment approach.From1 Aug 2019 → 11 Oct 2023Funding: FWO Strategic Basic Research Grant
- Comprehensive genomic and transcriptomic analysis of high grade serous ovarian cancer using single-cell RNA-sequencing.From1 Jan 2019 → 31 Dec 2021Funding: Foundations, funds and other with scientific goal
- Searching for new leads in the diagnosis of ovarian cancerFrom1 Oct 2017 → 30 Sep 2021Funding: Foundations, funds and other with scientific goal
- Comprehensive transcriptomic analysis of high-grade serous tubo-ovarian carcinoma using single-cell RNA-sequencing.From1 Mar 2017 → 5 Jul 2021Funding: Own budget, for example: patrimony, inscription fees, gifts
- From Never to Always Events: in search for mango-momentsFrom1 Nov 2016 → 31 Oct 2018Funding: Nonprofit institution or equivalents
- FIRST PET-MR: Flmeish interuniversity research simultaneous time-of-flight PET-MR scanner.From14 Aug 2014 → 13 Feb 2019Funding: Own budget, for example: patrimony, inscription fees, gifts
- Flemish interuniversity simultaneous time-of-flight PET-MR scanner for research.From14 Aug 2014 → 13 Feb 2019Funding: Hercules - Large scale research infrastructure
- A drug strategy targeting stabilised mutant p53 to fight metastatic plantinum-resistant ovarian cancer.From1 Oct 2013 → 31 Mar 2019Funding: General Activities (Annex IV)
- Dendritic cell immunotherapy in serous ovarian cancer.From1 Oct 2013 → 30 Sep 2016Funding: FWO fellowships
Publications
1 - 10 of 739
- Homologous recombination deficiency in ovarian cancer: Global expert consensus on testing and a comparison of companion diagnostics.(2025)
Authors: Ignace Vergote
Pages: 115169 - Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer.(2025)
Authors: Ignace Vergote
Pages: e240133 - Safety and quality of life with maintenance olaparib plus bevacizumab in older patients with ovarian cancer: subgroup analysis of PAOLA-1/ENGOT-ov25(2024)
Authors: Ignace Vergote
- Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial.(2024)
Authors: Ignace Vergote
Pages: S0923-7534 - Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ ENGOT-OV26/GOG-3012 trial(2024)
Authors: Ignace Vergote
Pages: 981 - 992 - Patterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease after fi rst-line chemotherapy: An ad hoc subgroup analysis of PRIMA/ENGOT-OV26/GOG-3012(2024)
Authors: Ignace Vergote
Pages: 68 - 74 - Gene expression markers in peripheral blood and outcome in patients with platinum-resistant ovarian cancer: A study of the European GANNET53 consortium(2024)
Authors: Ignace Vergote
Pages: 1128 - 1138 - Cemiplimab monotherapy in Japanese patients with recurrent or metastatic cervical cancer(2024)
Authors: Ignace Vergote
- Loss of copy numbers of retrotransposons (HERVK) on chromosome 7p11.2 impacts EGFR (Epidermal Growth Factor Receptor)-induced phenotypes for platinum sensitivity and long-term survival in ovarian cancer-A study from the OVCAD consortium(2024)
Authors: Toon Van Gorp, Ignace Vergote
Pages: 934 - 945 - ENGOT-EN20/GOG-3083/XPORT-EC-042-A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design(2024)
Authors: Ignace Vergote, Toon Van Gorp
Pages: 1283 - 1289
Patents
1 - 1 of 1
- Methods for diagnosing ovarian cancer (Inventor)